Read-only by design — Olmem never buys, sells, shorts, or places any order. This platform provides market research and decision-support tools only. It does not provide personalized financial advice, does not guarantee investment results, and does not execute trades. All investment decisions are the responsibility of the user.
← Scanner

ABTAbbott Laboratories

Healthcare·Medical Devices·NYSE·Mkt cap $190.00B
$92.64
-$1.29 (-1.37%) today
58/100 Opportunity
33Risk
66Momentum
66Pullback
65Quality
68Valuation
25Trend
Price & History (up to 5 years)
2025-07-112026-07-13
Low 82.56— support · — resistanceHigh 134.51
Technical Indicators
RSI (14)56.6
MACD hist0.29
ATR (14)2.35
SMA 2091.81
SMA 5089.19
SMA 200110.01
Rel volume0.7x
Boll upper97.23
Boll lower86.40
52w high135.33
52w low81.97
5y high137.75
5y low81.97
Hist. vol25%
Max drawdown-39%
Long-Term DowntrendBuy WatchPossible Dip BuyEntry: Pullback Watch
Company QualityStable
Revenue growth+8.0%
Earnings growth+10.0%
Profit margin+16.0%
ROE+20.0%
Debt/Equity0.60
Free cash flow
P/E22.0
Fwd P/E18.0
P/S4.0
P/B4.5
Div yield+1.5%

Abbott Laboratories — Medical Devices company in the Healthcare sector.

Decision SummaryInternal Rule-Based Analysis
Current Rating
Weak Setup
Opportunity Score
58/100
Risk Level
Low-Moderate
Best Action
Add to watchlist and monitor for confirmation

Why: ABT is trading near recent levels (-0.5% today). Overall, the company is reasonably solid. The long-term trend is down, which raises the bar for any bullish setup. Short-term momentum is still weak, so confirmation is needed before acting. This may be worth monitoring, but confirmation is needed before acting.

What to watch: Volume confirmation, hold of nearest support, next earnings date, sector strength, and news sentiment.

Avoid if: Price breaks below support on heavy volume or company guidance weakens.

Internal Rule-Based Analysis · Learning From Historical Outcomes. This rating comes from Olmem’s internal scoring and historical pattern tracking. It is not a guaranteed prediction.

Research only — not financial advice. Olmem never executes trades.

All Scores
Company Quality65
Historical Context50
Valuation68
Trend25
Momentum66
Pullback66
News Sentiment50
Business Move50
Sector Strength60
Risk/Reward100
Entry Timing55
Sell Risk32
Risk33

News & business-move scores come from Olmem’s rule-based news engine (keyword-classified headlines) — no AI. They default to a neutral 50 when there is no recent news.